Role of carbon nanoparticle suspension in sentinel lymph node biopsy for early-stage cervi

356 cases of stage Ia2-IIa2 cervical cancer patients were enrolled in a prospective study to evaluate carbon nanoparticle suspension (CNS) for sentinel lymph node biopsy. The study, conducted by researchers from the First Affiliated Hospital of Zhengzhou University, analyzed detection rates, sensitivity, and negative predictive value. Results showed an overall sentinel lymph node detection rate of 91.29%.

Use Cases

• Evaluate the diagnostic performance of sentinel lymph node biopsy based on detection rates and false-negative rates reported in the study.
• Analyze factors influencing biopsy success based on tumor size subgroups (<20 mm vs. ≥20 mm) mentioned in the results.
• Compare surgical outcomes for different patient subgroups based on variables like pathologic type, grade, and surgical approach analyzed in the study.

Strengths

• Prospective study design with 356 enrolled patients provides a substantial clinical cohort.
• Analysis includes multiple outcome measures: detection rate (91.29%), sensitivity (92.86%), and negative predictive value (99.29%).
• Subgroup analysis for patients with tumors <20 mm (267 cases) showed improved metrics (100% sensitivity, 0% false-negative rate).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Last update date is unknown; freshness unverified.

Provenance

Source

First Affiliated Hospital of Zhengzhou University

Collection Method

Prospective clinical study involving sentinel lymph node biopsy using carbon nanoparticle suspension followed by systematic pelvic lymphadenectomy.